Postoperative Outcomes in Patients With Hepato-biliary-pancreatic Cancer According to inBody Test

• Sponsor: Kochi University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05257434
• Collaborator: (none)
• Enrollment: 1,000
• Location: 1
• Anticipated Duration (Months): 133
• Patients Per Site Per Month: 7.5

Study Details

Study Description

Brief Summary

postoperative outcomes were evaluated by using inBody test

Condition or Disease	Intervention/Treatment	Phase
Cancer	Behavioral: inbody

Detailed Description

postoperative outcomes were evaluated by using inBody test

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 1000 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Postoperative Outcomes in Patients With Hepato-biliary-pancreatic Cancer According to inBody Test
• Actual Study Start Date: Jan 1, 2019
• Anticipated Primary Completion Date: Jan 31, 2025
• Anticipated Study Completion Date: Jan 31, 2030

Outcome Measures

Primary Outcome Measures

1. long-term outcomes [5year]

   overall survival rate

Secondary Outcome Measures

1. short-term outcomes [up to 24 weeks]

   postoperative complications

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 90 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• surgically treated patients

Exclusion Criteria:

• a body weight loss of >10% during the 6 months before surgery; the presence of distant metastases; or seriously impaired function of vital organs because of respiratory, renal, or heart disease

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Takehiro Okabayashi	Kochi		Japan	781-8555

Sponsors and Collaborators

• Kochi University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Takehiro Okabayashi, Department of Gastroenterological Surgery, Kochi University
• ClinicalTrials.gov Identifier: NCT05257434
• Other Study ID Numbers: Point study
• First Posted: Feb 25, 2022
• Last Update Posted: Feb 25, 2022
• Last Verified: Feb 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Feb 25, 2022